{"gene":"MZF1","run_date":"2026-04-29T11:37:56","timeline":{"discoveries":[{"year":1994,"finding":"MZF1 contains two independent DNA-binding domains (zinc fingers 1–4 and 5–13) that each recognize distinct but related G-rich consensus sequences (1–4: 5'-AGTGGGGA-3'; 5–13: 5'-CGGGnGAGGGGGAA-3'), as determined by affinity selection from degenerate oligonucleotide libraries and gel-shift assays with purified recombinant protein.","method":"SELEX/affinity selection from degenerate oligonucleotide library, gel-shift (EMSA) with purified recombinant protein domains","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with purified recombinant protein, two orthogonal methods, foundational study replicated by later work","pmids":["8114711"],"is_preprint":false},{"year":1991,"finding":"MZF1 is preferentially expressed in myeloid cells (highest in HL-60 cells induced with retinoic acid) and encodes a protein with 13 C2H2 zinc fingers arranged in two domains separated by a glycine-proline-rich region, localised to chromosome 19q13.2-4.","method":"cDNA library screening, sequence analysis, Northern blot, chromosomal mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — original cloning and characterization paper, multiple orthogonal methods, highly cited foundational work","pmids":["1860835"],"is_preprint":false},{"year":1991,"finding":"MZF-1 antisense (but not sense) oligonucleotides significantly inhibited G-CSF-driven granulocyte colony formation in vitro, demonstrating a required role for MZF-1 in granulopoiesis.","method":"Antisense oligonucleotide inhibition of granulocyte colony formation in vitro","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — clean loss-of-function with defined cellular phenotype, single lab","pmids":["1719120"],"is_preprint":false},{"year":1995,"finding":"MZF1 acts as a bifunctional transcriptional regulator of the CD34 promoter: it represses transcription in non-hematopoietic cell lines (NIH 3T3, 293) and activates transcription in hematopoietic cell lines (K562, Jurkat), with activation dependent on intact MZF1 binding sites in the CD34 promoter.","method":"GAL4 fusion cotransfection reporter assay (CAT/luciferase), EMSA with recombinant MZF1, site-directed mutagenesis of binding sites","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with recombinant protein, reporter mutagenesis, multiple cell lines tested","pmids":["7579328"],"is_preprint":false},{"year":1995,"finding":"Constitutive MZF1 overexpression in embryonic stem cells inhibits hematopoietic commitment and prevents induced expression of CD34 and c-myb; MZF1 binds MZF1 consensus sites in the CD34 and c-myb promoters and represses their transcriptional activity in co-transfection assays.","method":"Retroviral/stable transfection into ES cells, EMSA with recombinant MZF1, CAT reporter assay, RT-PCR","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal methods, loss- and gain-of-function, in vitro DNA binding confirmed","pmids":["7565760"],"is_preprint":false},{"year":1995,"finding":"Retroviral overexpression of MZF-1 in NIH 3T3 fibroblasts causes loss of contact inhibition, loss of substrate dependence, more rapid cell cycling, and formation of aggressive tumors in athymic mice, establishing MZF-1 as an oncogene when aberrantly expressed.","method":"Retroviral transduction, focus formation assay, nude mouse tumorigenesis assay","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function with defined oncogenic phenotype in vitro and in vivo, multiple readouts","pmids":["7627970"],"is_preprint":false},{"year":1995,"finding":"The human MZF-1 gene is intronless, spans ~3 kb, is a single-copy gene, and its promoter contains retinoic acid response elements and GM-CSF-responsive sequences that drive transcriptional responsiveness; MZF-1 can also auto-regulate its own expression via consensus zinc finger binding sites in its promoter.","method":"Genomic cloning, PCR, primer extension, CAT reporter assay with deletion constructs, retroviral overexpression in K562 cells","journal":"Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — promoter analysis with functional reporter assays, auto-regulation demonstrated by ectopic expression","pmids":["8845378"],"is_preprint":false},{"year":1996,"finding":"Retroviral overexpression of MZF-1 in IL-3-dependent FDCP.1 cells inhibits apoptosis upon IL-3 withdrawal and confers tumorigenic potential in vivo, showing MZF-1 promotes cell survival and oncogenesis in a hematopoietic context.","method":"Retroviral transduction, apoptosis assay upon cytokine withdrawal, syngeneic mouse tumor formation assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — gain-of-function with defined apoptosis and tumorigenesis phenotypes","pmids":["8667641"],"is_preprint":false},{"year":1998,"finding":"Overexpression of MZF-1 in HL-60 cells delays retinoic acid-induced apoptosis and differentiation, sustains proliferation (higher S-phase fraction), reduces CD18 expression after 6 days RA, and is associated with prolonged bcl-2 expression; MZF-1 had no effect on PMA-induced monocyte/macrophage differentiation.","method":"Retroviral transduction/overexpression in HL-60 cells, TUNEL, DNA fragmentation, flow cytometry, Western blot for bcl-2","journal":"Leukemia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal readouts (TUNEL, DPA, flow cytometry, bcl-2 protein), mechanistic link to bcl-2","pmids":["9593266"],"is_preprint":false},{"year":2000,"finding":"The SCAN box (leucine-rich domain) present only in the MZF1B isoform mediates homo- and heterodimeric protein-protein interactions: MZF1B self-associates via its SCAN box and binds the novel SCAN-related protein RAZ1 (identified by yeast two-hybrid screening of a bone marrow library), as confirmed by co-immunoprecipitation.","method":"Yeast two-hybrid screen, co-immunoprecipitation, in vitro association assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP plus yeast two-hybrid, domain mapping performed","pmids":["10777584"],"is_preprint":false},{"year":2001,"finding":"Gene-targeted Mzf1-/- mice develop lethal myeloid neoplasias with liver infiltration by chloroma-like myeloid cells, and Mzf1-/- hematopoietic progenitors show striking increases in autonomous proliferation and long-term hematopoietic capacity, demonstrating that Mzf1 acts as a tumor/growth suppressor in the hematopoietic compartment.","method":"Gene targeting (knockout mouse), histopathology, hematopoietic colony and long-term culture assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean KO mouse with defined cellular and tumor phenotype, replicated across multiple assays","pmids":["11445537"],"is_preprint":false},{"year":2005,"finding":"MZF1 binds to a GA-rich core element in the N-cadherin proximal promoter in osteoblasts (identified by EMSA/supershift); cotransfection shows MZF1 overexpression increases N-cadherin promoter activity and N-cadherin mRNA expression, while Sp1/MZF1 together further enhance this effect.","method":"EMSA with osteoblast nuclear extracts and competition/supershift assays, deletion/mutation analysis, cotransfection luciferase reporter assay, RT-PCR","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA with nuclear extracts plus functional reporter with mutagenesis, single lab","pmids":["15541732"],"is_preprint":false},{"year":2005,"finding":"MZF1 is part of a novel LTR enhancer complex NF-Y/MZF1/GATA-2 at the ERV-9 LTR upstream of the beta-globin locus: NF-Y bound at CCAAT motifs recruits MZF1 (via protein-protein interaction) and GATA-2 to neighboring GTGGGGA and GATA sites; mutation of the CCAAT motif abolishes NF-Y binding and silences downstream gene transcription.","method":"EMSA, co-IP/protein-protein interaction assays, chromatin structure analysis, stable reporter assay in K562 cells with promoter mutation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal methods, functional mutagenesis in stable cell line, identifies protein-protein interaction hierarchy","pmids":["16105833"],"is_preprint":false},{"year":2005,"finding":"MZF-1 transcriptionally activates PKCα expression in poorly differentiated HCC cells; antisense MZF-1 oligonucleotides reduce both MZF-1 and PKCα mRNA levels and decrease cell proliferation, migration, and invasion.","method":"Antisense oligonucleotide knockdown, RT-PCR, antisense vs. sense oligonucleotide controls, migration/invasion assays, EMSA for promoter binding","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — antisense loss-of-function with multiple functional readouts, promoter binding confirmed by EMSA","pmids":["16297876"],"is_preprint":false},{"year":2005,"finding":"MZF-1 interacts with the apoptosis-inducing leucine-zipper protein LDOC1 and enhances LDOC1-mediated apoptosis, as shown by co-immunoprecipitation and functional apoptosis assays.","method":"Co-immunoprecipitation, phosphatidylserine externalization assay, mitochondrial membrane potential assay, caspase-3 activity assay","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 3 — single co-IP with functional follow-up, single lab","pmids":["15670815"],"is_preprint":false},{"year":2006,"finding":"MZF1 binds to a MZF1-like site in the ERCC1 promoter (EMSA with consensus oligonucleotides) and overexpression of MZF1 represses ERCC1 promoter activity; cisplatin treatment decreases MZF1 mRNA and binding activity, coinciding with increased AP1 binding and ERCC1 upregulation.","method":"EMSA, CAT reporter cotransfection assay, quantitative PCR","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA plus functional reporter assay, mechanistic link to drug response, single lab","pmids":["16426580"],"is_preprint":false},{"year":2006,"finding":"The MZF1 SCAN domain forms a domain-swapped homodimer with a Kd ~600 nM; residues from helix 3 compose the core dimer interface; the structure was determined by NMR spectroscopy and validated by GST pull-down self-association assays.","method":"NMR structure determination, GST pull-down, tryptophan fluorescence polarization Kd measurement","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with biochemical validation, Kd determined, structure-function analysis","pmids":["16950398"],"is_preprint":false},{"year":2007,"finding":"MZF1 and Sp1/Sp3 bind to the PADI1 (peptidylarginine deiminase type I) promoter in keratinocytes in vivo (confirmed by ChIP); mutation of MZF1 or Sp1 binding sites markedly reduces PADI1 promoter activity, and siRNA knockdown of MZF1 or Sp1 diminishes PADI1 expression in both low- and high-calcium conditions.","method":"Luciferase reporter with deletion/mutation constructs, ChIP assay, siRNA knockdown, qRT-PCR","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 1/2 — ChIP confirms in vivo binding, mutagenesis, siRNA knockdown with defined molecular phenotype","pmids":["17851584"],"is_preprint":false},{"year":2009,"finding":"MZF-1 transcriptionally activates the FGF-2 promoter in striatal astrocytes in response to apomorphine (D1/D2 receptor agonist): a cis-element in the -785/-745 region of the FGF-2 promoter is recognized by MZF-1, and MZF-1 overexpression increases FGF-2 protein levels while MZF-1 siRNA reduces promoter activity.","method":"Promoter deletion/reporter assay, EMSA, MZF-1 plasmid overexpression and siRNA knockdown, FGF-2 protein quantification","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mapping, EMSA, and bidirectional (OE/KD) validation, single lab","pmids":["19196427"],"is_preprint":false},{"year":2012,"finding":"MZF1 transcriptionally activates the p55PIK (regulatory subunit of PI3K) gene by directly binding to the TGGGGA cis-element in the p55PIK promoter (confirmed by ChIP); MZF1 overexpression increases p55PIK promoter activity and expression, leading to increased colorectal cancer cell proliferation, while MZF1 silencing has the opposite effects.","method":"ChIP assay, luciferase reporter assay, MZF1 overexpression/siRNA knockdown, cell proliferation assay","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding, bidirectional functional validation","pmids":["23509792"],"is_preprint":false},{"year":2014,"finding":"MZF-1 transcriptionally regulates ferroportin (FPN) expression; increased MZF-1 promotes FPN-driven iron egress, reducing intracellular iron and restraining prostate tumor cell growth, while inhibition of MZF-1 reduces FPN, causes iron retention and enhanced tumor growth. AP4 and c-Myb jointly activate MZF1 transcription, and miR-492 directly inhibits MZF1 via its 3'UTR.","method":"siRNA/shRNA knockdown, overexpression, iron assay, xenograft tumor model, luciferase reporter for miR-492 3'UTR binding, qRT-PCR, Western blot","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods, bidirectional manipulation, in vivo confirmation, upstream regulation characterized","pmids":["25284586"],"is_preprint":false},{"year":2014,"finding":"OPN (osteopontin) induces integrin-dependent MSC expression of TGF-β1, which mediates MSC-to-CAF transformation; this pathway requires MZF1 as a transcription factor, and MZF1/TGF-β1-dependent CAF transformation promotes tumor growth and metastasis in xenograft models.","method":"In vitro co-culture with human MSCs and breast cancer lines, in vivo xenograft in NOD-scid mice, loss-of-function with siRNA/shRNA for MZF1 and TGF-β1, tumor growth/metastasis readouts","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — in vitro and in vivo validation, loss-of-function with defined pathway placement","pmids":["25531323"],"is_preprint":false},{"year":2014,"finding":"LKB1 loss leads to increased MZF1 expression, which in turn drives MYC transcription; the MZF1/MYC axis mediates soft-agar growth, migration, and invasion in lung adenocarcinoma cells, and MYC inhibitors suppress LKB1-loss-induced invasiveness.","method":"shRNA knockdown of LKB1/MZF1, luciferase reporter for MYC promoter, MYC inhibitor treatment, soft-agar and invasion assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis established by knockdown plus promoter reporter, pharmacological validation","pmids":["24793789"],"is_preprint":false},{"year":2014,"finding":"MZF1 directly binds the SMAD4 promoter core region (confirmed by EMSA and luciferase reporter with mutations) and activates SMAD4 transcription; MZF1 expression reduces migration of gastric adenocarcinoma cells, establishing an MZF1-SMAD4 tumor-suppressive axis.","method":"EMSA, luciferase reporter with site-directed mutagenesis, ChIP, wound-healing/Transwell migration assay","journal":"International journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 — EMSA plus reporter mutagenesis plus ChIP, functional migration assay, single lab","pmids":["27922669"],"is_preprint":false},{"year":2014,"finding":"MZF1 is required for FOXM1 upregulation by HPV E6 oncoprotein through the MZF1/NKX2-1 axis; NKX2-1 induced by E6 drives MZF1-mediated transcription of FOXM1, which activates Wnt/β-catenin signaling to promote tumor aggressiveness, invasiveness, and stemness.","method":"shRNA knockdown of E6/MZF1/FOXM1, luciferase reporter, nude mouse metastasis model, FOXM1 inhibitor (thiostrepton)","journal":"Neoplasia","confidence":"Medium","confidence_rationale":"Tier 2 — epistasis by sequential knockdowns in vitro and in vivo, pathway placement, single lab","pmids":["25425970"],"is_preprint":false},{"year":2015,"finding":"MZF1 and Elk-1 form a heterodimeric complex that binds the PKCα promoter; Elk-1 binds the N-terminal region of MZF1 and MZF1 binds the C-terminal region of Elk-1 (confirmed by Co-IP, Re-ChIP); DNA-binding-deficient mutants of either factor reduce PKCα expression, cell proliferation, migration, invasion, and tumorigenicity in HCC.","method":"Co-IP, ChIP, Re-ChIP, luciferase reporter with DNA-binding-deficient mutants, migration/invasion/tumorigenicity assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1/2 — direct protein-protein interaction domain mapping by Co-IP, Re-ChIP confirms complex at promoter, domain mutants used for functional analysis","pmids":["26010542"],"is_preprint":false},{"year":2015,"finding":"MZF1 suppresses IGF-IR gene promoter activity in NPM-ALK+ T-cell lymphoma (confirmed by luciferase assay and ChIP); forced MZF1 expression reduces IGF-IR mRNA/protein and downstream pIGF-IR, IRS-1, AKT, and NPM-ALK phosphorylation, and decreases lymphoma cell viability, proliferation, migration, and colony formation.","method":"Luciferase reporter assay, ChIP, forced overexpression, Western blot for downstream signaling, viability/proliferation/migration/colony assays","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirms direct promoter binding, pathway epistasis shown by signaling cascade analysis, multiple functional readouts","pmids":["25884514"],"is_preprint":false},{"year":2016,"finding":"The acidic domain (residues 60–72) of MZF-1 interacts with the heparin-binding domain (residues 145–157) of Elk-1 to form a heterodimer; blocking this interaction with peptide fragments (MZF-160-72 or Elk-1145-157) decreases MZF-1/Elk-1 complex formation, reduces PKCα promoter binding, and suppresses PKCα expression, migration, tumorigenicity, and EMT in triple-negative breast cancer cells.","method":"Peptide transfection to block protein-protein interaction, luciferase reporter, ChIP for PKCα promoter binding, rescue by full-length PKCα","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1/2 — domain-level PPI mapping with peptide interference, functional rescue experiment, multiple orthogonal readouts","pmids":["27542222"],"is_preprint":false},{"year":2016,"finding":"MZF1 directly binds the mutational landscape of the MZF1 SCAN domain as assessed by NMR-validated conformational ensemble; the SCAN domain mediates homo- and heterodimerization and its cancer-related substitutions perturb the protein-protein interaction network of MZF1.","method":"NMR spectroscopy, molecular dynamics simulations, proteomics/RNASeq data analysis","journal":"Frontiers in molecular biosciences","confidence":"Medium","confidence_rationale":"Tier 1 — structural NMR with computational analysis, but functional validation of specific cancer mutations is computational only","pmids":["28018905"],"is_preprint":false},{"year":2017,"finding":"TGF-β1 induces CK17 expression in cervical cancer cells via the ERK1/2-MZF1 signaling pathway; ERK1/2 inhibitors block CK17 induction, and MZF1 directly binds the CK17 promoter as identified and validated by combined computational and experimental approaches; CK17 promotes cancer stem cell properties and lymphatic metastasis without inducing EMT.","method":"ERK1/2 inhibitor treatment, MZF1 promoter binding validation (ChIP/EMSA), shRNA knockdown, in vivo metastasis assay","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 — pathway epistasis via inhibitor, direct binding confirmed, in vivo functional readout","pmids":["28703907"],"is_preprint":false},{"year":2017,"finding":"MZF1 upregulates PRAME expression via direct binding to intron DNA containing MZF1 binding sites overlapping a CpG-rich region; MZF1 binding is enhanced by DNA demethylation (5-azaC treatment), and MZF1 promotes colony-forming ability in melanoma cells.","method":"Luciferase reporter, EMSA, ChIP, 5-azaC treatment, overexpression assay, colony formation assay","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus EMSA confirms direct binding, functional link to methylation status, single lab","pmids":["28634046"],"is_preprint":false},{"year":2018,"finding":"FTO (m6A demethylase) enhances MZF1 mRNA expression in lung squamous cell carcinoma by reducing m6A levels on MZF1 mRNA, thereby increasing MZF1 mRNA stability; FTO knockdown decreases MZF1 expression and inhibits cell proliferation and invasion.","method":"m6A quantification, MZF1 mRNA stability assay, FTO knockdown/overexpression (including catalytic mutant), cell proliferation/apoptosis/invasion assays","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — mechanism established by catalytic mutant of FTO (distinguishes enzymatic from non-enzymatic effects), mRNA stability assay, multiple functional readouts","pmids":["29842885"],"is_preprint":false},{"year":2018,"finding":"CK2 directly interacts with MZF1 and phosphorylates it at serine 27, which stabilizes MZF1 protein; phosphorylation-stabilized MZF1 then drives N-cadherin transcription (confirmed by ChIP), promoting EMT, cell motility and invasiveness; MZF1 knockdown reverts cancer cells from mesenchymal to epithelial morphology.","method":"Co-IP (direct CK2-MZF1 interaction), phosphorylation site mapping (S27), protein stability assay, ChIP for N-cadherin promoter, morphological analysis, migration/invasion assay","journal":"Oncogenesis","confidence":"High","confidence_rationale":"Tier 1/2 — post-translational modification by identified kinase (CK2), phosphorylation site identified, ChIP confirms downstream transcription, multiple functional readouts","pmids":["29540671"],"is_preprint":false},{"year":2018,"finding":"CHIP/STUB1 ubiquitin ligase negatively regulates MZF1 DNA-binding activity in the nucleus; loss of nuclear CHIP unleashes MZF1-driven transcription of cathepsin B/L (CTSB/L), promoting tumor cell invasion and xenograft growth in ErbB2+ breast cancer cells.","method":"Unbiased transcription factor activity screen, ectopic CHIP expression, CTSB inhibition, xenograft growth assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — unbiased screen identifies MZF1 as CHIP target, gain-of-function with defined molecular and cellular phenotype, single lab","pmids":["29510992"],"is_preprint":false},{"year":2019,"finding":"MZF1-AS1 lncRNA binds PARP1 and facilitates PARP1 interaction with E2F1, resulting in E2F1 transactivation and upregulation of MZF1 and other oncogenic genes; MZF1 in turn promotes aldehyde dehydrogenase 18A1 and PYCR1 expression to drive proline synthesis in neuroblastoma; a peptide blocking MZF1-AS1/PARP1 interaction suppresses tumor progression.","method":"RNA pulldown, co-IP (PARP1-E2F1), ChIP, luciferase reporter, small peptide blocking, lentiviral shRNA, in vivo tumor assay, amino acid profiling","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1/2 — RNA pulldown plus Co-IP identifies ternary complex, ChIP confirms transcriptional regulation, pharmacological and genetic validation in vivo","pmids":["31592410"],"is_preprint":false},{"year":2019,"finding":"Sublytic C5b-9 activates the FBXO28-TRAF6 complex, which promotes K63-ubiquitination and phosphorylation of ERK5; activated ERK5 drives MZF1 expression, which then binds the RGC-32 promoter to upregulate RGC-32, causing glomerular mesangial cell proliferation in rat Thy-1 nephritis.","method":"Co-IP (FBXO28-TRAF6-ERK5), ubiquitination assay, ChIP for MZF1 at RGC-32 promoter, luciferase reporter, gene knockdown in vivo (siRNA), histology","journal":"Journal of cellular and molecular medicine","confidence":"High","confidence_rationale":"Tier 2 — protein complex identified by Co-IP, ChIP confirms MZF1-RGC-32 promoter binding, in vivo validation by gene silencing","pmids":["31184423"],"is_preprint":false},{"year":2019,"finding":"MZF1 in dorsal root ganglia promotes TRPV1 expression (but not P2X7R) and contributes to neuropathic pain; CCI increases MZF1 and TRPV1 in L4/5 DRGs; viral overexpression of MZF1 induces allodynia and hyperalgesia in naïve rats, while MZF1 siRNA ameliorates CCI-induced pain behaviors.","method":"rAAV5 viral overexpression of MZF1 in DRG, MZF1 siRNA microinjection, behavioral pain testing (PWT, PWL), Western blot for TRPV1 and P2X7R","journal":"Neural plasticity","confidence":"Medium","confidence_rationale":"Tier 2 — bidirectional in vivo manipulation with defined behavioral phenotype, target gene specificity shown","pmids":["31582966"],"is_preprint":false},{"year":2019,"finding":"MZF1 transcriptionally activates the Mtor promoter in a strain-specific manner in mice: a T (vs. C) at -6 relative to Tssr 40273 creates an MZF1 consensus binding site; MZF1 binds this TGGGGA element (confirmed by EMSA, DNA pulldown, and ChIP-PCR) and overexpression of MZF1 reduces Mtor promoter activity more strongly in BALB mice than DBA mice.","method":"EMSA, DNA pulldown, ChIP-PCR, luciferase reporter with allelic variants, MZF1 overexpression and Mzf1 knockdown in fibroblasts and plasmacytoma cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 — multiple biochemical methods confirm direct binding to specific site, functional reporter with allelic variants, bidirectional genetic manipulation","pmids":["31548308"],"is_preprint":false},{"year":2020,"finding":"Linc01060 (lncRNA from hypoxic glioma stem cell exosomes) directly interacts with MZF1 and enhances its protein stability and nuclear translocation, enabling MZF1-mediated c-Myc transcriptional activation; c-Myc then enhances HIF1α accumulation post-transcriptionally; HIF1α feeds back by binding the Linc01060 promoter to upregulate Linc01060 transcription.","method":"RNA-protein interaction assay (Linc01060-MZF1), subcellular fractionation (nuclear translocation), co-IP, luciferase reporter (MZF1/c-Myc promoter), ChIP (HIF1α at Linc01060 promoter)","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — RNA-protein interaction shown, subcellular localization with functional consequence, ChIP and reporter confirm pathway, feedback loop established","pmids":["33158815"],"is_preprint":false},{"year":2020,"finding":"YY1 transcription factor drives MZF1 transcription; a 21-amino acid upstream open reading frame-encoded peptide (MZF1-uPEP) binds the zinc finger domain of YY1 and represses YY1 transactivation, thereby reducing MZF1 and its downstream glycolytic targets HK2 and PGK1 in neuroblastoma.","method":"Dual-luciferase assay, ChIP, Co-IP, mass spectrometry, peptide pull-down, sucrose gradient sedimentation, seahorse metabolic flux, soft agar, in vivo nude mouse assay","journal":"Theranostics","confidence":"High","confidence_rationale":"Tier 1/2 — multiple orthogonal biochemical methods, peptide pull-down identifies binding domain, in vivo validation","pmids":["32042322"],"is_preprint":false},{"year":2021,"finding":"MZF1 mediates oncogene-induced senescence by recruiting CHD7 to the p16INK4A (CDKN2A) promoter to drive p16INK4A transcription; MZF1 expression is itself induced by oncogenic Ras through c-Jun and Ets1 transcription factors activated by the Ras-Raf-1-MEK-ERK signaling pathway.","method":"ChIP (MZF1 and CHD7 at p16INK4A promoter), reporter assay, knockdown of MZF1/CHD7, epistasis in primary human cells from multiple origins, signaling pathway inhibitors","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — ChIP confirms direct promoter recruitment, epistasis via inhibitors, multiple cell types validated","pmids":["34773072"],"is_preprint":false},{"year":2021,"finding":"GSK3β mediates ubiquitination of FTO demethylase, reducing FTO expression; this increases m6A modification of MZF1 mRNA, suppressing MZF1 expression and consequently decreasing c-Myc, thereby inhibiting colorectal carcinoma cell proliferation.","method":"Ubiquitination assay, m6A methylation assay on MZF1 mRNA, MZF1-FTO interaction assay (co-IP), overexpression/knockdown, in vivo tumor model with c-Myc rescue","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical mechanism of ubiquitination-dependent m6A regulation demonstrated, in vivo rescue confirms pathway, single lab","pmids":["33533172"],"is_preprint":false},{"year":2021,"finding":"Irradiation upregulates MZF1, which transcriptionally represses miR-541-5p (and its primary precursor pri-miR-541-5p); reduced miR-541-5p de-represses Slug, promoting EMT and radiation-induced pulmonary fibrosis; ectopic miR-541-5p mitigates RIPF in vivo.","method":"Irradiation model in vitro and in vivo (mouse RIPF), MZF1 knockdown/overexpression, luciferase reporter for miR-541-5p promoter, Slug knockdown, EMT marker analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — transcriptional repression of miRNA by MZF1 established with reporter assay, pathway epistasis via Slug knockdown, in vivo validation","pmids":["34768749"],"is_preprint":false},{"year":2022,"finding":"SETD8 (histone methyltransferase) and MZF1 co-occupy the WNT5A promoter and cooperate to regulate WNT5A expression in human glomerular endothelial cells; high glucose increases MZF1 expression and decreases SETD8 expression; SETD8 silencing expands MZF1 enrichment on the WNT5A promoter, increasing WNT5A transcription and downstream NF-κB-mediated inflammation.","method":"Co-IP (MZF1-SETD8), ChIP (MZF1 and SETD8/H4K20me1 at WNT5A promoter), dual luciferase reporter, siRNA knockdown, immunofluorescence, in vivo DN rat model","journal":"Cellular & molecular biology letters","confidence":"High","confidence_rationale":"Tier 2 — Co-IP identifies MZF1-SETD8 interaction, ChIP confirms both factors at same promoter, in vivo rat model with rescue experiment","pmids":["35350980"],"is_preprint":false},{"year":2023,"finding":"MZF1 promotes PD-L1 ubiquitination and degradation by binding to the CDK4 activation site; CDK4 directly binds MZF1 and increases MZF1 expression; in turn, elevated MZF1 suppresses T-cell recruitment and confers resistance to anti-PD-L1 immunotherapy in hepatocellular carcinoma.","method":"Protein degradation assay, ubiquitination assay, co-IP (MZF1-CDK4), orthotopic and hydrodynamic mouse HCC models, CDK4 inhibitor treatment","journal":"JHEP reports","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and ubiquitination assays identify mechanism, in vivo pharmacological rescue, single lab","pmids":["38074509"],"is_preprint":false},{"year":2023,"finding":"UHRF1/DNMT1 complex hypermethylates an intragenic CpG island (iCpGI) in the PRSS3 gene, interfering with MZF1 binding and suppressing PRSS3-V3 expression; site-specific iCpGI demethylation (by diallyl trisulfide + 5-aza-dC) allows MZF1 to access the PRSS3 promoter and upregulate tumor-suppressive PRSS3-V3 in lung cancer cells.","method":"ChIP, luciferase reporter, bisulfite sequencing, co-IP (UHRF1-DNMT1), drug treatment, isoform-specific expression analysis","journal":"Acta pharmaceutica Sinica B","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP confirms methylation-dependent MZF1 binding, epigenetic mechanism validated by drug treatment, single lab","pmids":["37250150"],"is_preprint":false},{"year":2023,"finding":"SLC1A5-AS lncRNA directly binds MZF1 protein (confirmed by biotin-labeled probe pulldown and western blot), sequestering MZF1 away from the SLC1A5 promoter and relieving MZF1-mediated repression, leading to increased ASCT2 expression and enhanced glutamine uptake in hepatocellular carcinoma.","method":"Biotin-labeled RNA probe pulldown (SLC1A5-AS/MZF1 interaction), luciferase reporter, ChIP, Western blot, glutamine uptake assay, in vivo xenograft","journal":"Discovery medicine","confidence":"Medium","confidence_rationale":"Tier 2 — RNA-protein interaction by probe pulldown, ChIP and luciferase confirm MZF1-promoter binding, single lab","pmids":["38058065"],"is_preprint":false},{"year":2025,"finding":"MZF1 forms intranuclear nuclear bodies (MZF1-NBs) that associate with PML-NBs; MZF1 is SUMO1-SUMOylated in PC-3 cells, enabling interaction with SUMO-interaction motif (SIM)-containing proteins; interactome analysis identifies MZF1-NB participation in stress response (TPR, UBAP2L), protein folding (CALR, ANKRD40), post-translational modification (TRIM33, CAMK2D, CAMK2G), and RNA binding (ALURBP, CPSF5).","method":"Live-cell imaging/immunofluorescence (nuclear body identification), proteomic/interactome analysis, SUMOylation assay, protein-protein interaction analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — direct subcellular localization experiment with functional consequence (nuclear body formation), SUMOylation identified, interactome by MS","pmids":["39954358"],"is_preprint":false}],"current_model":"MZF1 is a bifunctional C2H2 zinc-finger transcription factor with two independent DNA-binding domains (ZF1–4 and ZF5–13) that recognize G-rich consensus sequences; it also contains a SCAN domain that forms domain-swapped homodimers and mediates heterodimerization with partners such as RAZ1 and Elk-1; it is stabilized by CK2-mediated phosphorylation at S27 and regulated by FTO-dependent m6A methylation of its mRNA; nuclear MZF1 forms sumoylated nuclear bodies associated with PML-NBs; acting as a context-dependent transcriptional activator or repressor of targets including CD34, c-myb, CDKN2A/p16INK4A, ferroportin, N-cadherin, IGF1R, c-MYC, VEGF, TRPV1, and multiple other genes, MZF1 controls hematopoietic differentiation, oncogene-induced senescence, iron homeostasis, EMT, glycolytic and proline metabolic reprogramming, and neuropathic pain, with its oncogenic or tumor-suppressive output determined by cellular context, interacting cofactors (NF-Y, GATA-2, SETD8, CHD7, CHIP/STUB1, CDK4), and upstream lncRNA regulators such as Linc01060 and MZF1-AS1."},"narrative":{"teleology":[{"year":1991,"claim":"Identification of MZF1 as a myeloid-enriched 13-zinc-finger transcription factor established the gene's tissue-specific expression pattern and structural framework, answering what kind of regulatory protein it encodes.","evidence":"cDNA library screening, Northern blot, and chromosomal mapping in myeloid cell lines","pmids":["1860835"],"confidence":"High","gaps":["No DNA-binding specificity or target genes identified","Protein function unknown beyond structural prediction"]},{"year":1991,"claim":"Antisense inhibition of MZF1 blocked granulocyte colony formation, providing the first functional evidence that MZF1 is required for myeloid differentiation.","evidence":"Antisense oligonucleotide treatment of G-CSF-driven colony assays","pmids":["1719120"],"confidence":"Medium","gaps":["Antisense approach lacks modern specificity controls","Target genes mediating the differentiation effect unknown"]},{"year":1994,"claim":"Defining two independent DNA-binding domains with distinct G-rich consensus sequences resolved how MZF1 recognizes DNA and explained its capacity to regulate diverse promoters.","evidence":"SELEX from degenerate oligonucleotide libraries and EMSA with purified recombinant domains","pmids":["8114711"],"confidence":"High","gaps":["No in vivo target gene validation","Structural basis of DNA recognition not yet determined"]},{"year":1995,"claim":"Demonstrating that MZF1 acts as an activator in hematopoietic cells but a repressor in non-hematopoietic cells on the same CD34 promoter established MZF1's context-dependent bifunctionality, while overexpression-induced transformation of NIH 3T3 cells revealed its oncogenic potential.","evidence":"Reporter assays across multiple cell types; retroviral overexpression with focus formation and nude mouse tumorigenesis","pmids":["7579328","7627970","7565760"],"confidence":"High","gaps":["Cofactors determining activator vs. repressor switch unidentified","Mechanism of transformation not molecularly defined"]},{"year":2000,"claim":"Discovery that the SCAN domain mediates homodimerization and heterodimerization with RAZ1 revealed MZF1's capacity for combinatorial protein-protein interactions beyond DNA binding.","evidence":"Yeast two-hybrid screen of bone marrow library followed by reciprocal co-immunoprecipitation","pmids":["10777584"],"confidence":"High","gaps":["Functional consequence of RAZ1 interaction on transcription unknown","Full repertoire of SCAN-mediated partners not mapped"]},{"year":2001,"claim":"Mzf1 knockout mice developing lethal myeloid neoplasias resolved the paradox of MZF1's dual nature by proving it functions as a tumor/growth suppressor in the hematopoietic compartment in vivo.","evidence":"Gene-targeted Mzf1−/− mice with histopathology and hematopoietic colony/long-term culture assays","pmids":["11445537"],"confidence":"High","gaps":["Direct transcriptional targets mediating tumor suppression not identified","Whether overexpression transforms hematopoietic cells in vivo not tested"]},{"year":2005,"claim":"Identification of an NF-Y/MZF1/GATA-2 enhancer complex at the ERV-9 LTR and MZF1's activation of N-cadherin and PKCα broadened the target gene repertoire beyond hematopoiesis into bone biology and hepatocellular carcinoma.","evidence":"EMSA, co-IP, ChIP, and reporter mutagenesis in osteoblasts, K562, and HCC cells","pmids":["16105833","15541732","16297876"],"confidence":"High","gaps":["In vivo relevance of NF-Y/MZF1/GATA-2 complex for globin expression not shown","How MZF1 selects targets in different tissues unclear"]},{"year":2006,"claim":"NMR structure of the SCAN domain homodimer revealed a domain-swapped architecture with ~600 nM affinity, providing the first atomic-resolution view of MZF1's dimerization interface.","evidence":"NMR spectroscopy with GST pull-down and tryptophan fluorescence polarization","pmids":["16950398"],"confidence":"High","gaps":["Structure of zinc-finger domains bound to DNA not solved","How SCAN dimerization modulates transcriptional output unknown"]},{"year":2015,"claim":"Mapping the MZF1–Elk-1 heterodimer interface (MZF1 acidic domain–Elk-1 heparin-binding domain) and showing that peptide disruption suppresses PKCα-driven EMT and tumorigenesis established a druggable protein-protein interaction axis.","evidence":"Co-IP, Re-ChIP, domain-mapping, peptide interference, and functional rescue in breast cancer and HCC cells","pmids":["26010542","27542222"],"confidence":"High","gaps":["In vivo pharmacokinetics and specificity of blocking peptides not characterized","Whether Elk-1 interaction is required for all MZF1 oncogenic programs unknown"]},{"year":2018,"claim":"CK2 phosphorylation at S27 was shown to stabilize MZF1 protein and drive N-cadherin-dependent EMT, while FTO-mediated m6A demethylation was shown to stabilize MZF1 mRNA, together revealing two layers of post-transcriptional/post-translational MZF1 regulation.","evidence":"Phosphorylation site mapping with kinase co-IP (CK2); FTO catalytic mutant with m6A quantification and mRNA stability assay","pmids":["29540671","29842885"],"confidence":"High","gaps":["Other phosphorylation sites and kinases not systematically surveyed","Whether CK2 and FTO pathways converge in the same tumor context unknown"]},{"year":2019,"claim":"The lncRNA MZF1-AS1 was found to recruit PARP1 to E2F1, driving MZF1 transcription and downstream proline synthesis, while MZF1 in dorsal root ganglia was linked to TRPV1-dependent neuropathic pain, greatly expanding MZF1's functional scope beyond cancer.","evidence":"RNA pulldown, co-IP, ChIP, metabolic flux in neuroblastoma; viral overexpression/siRNA in rat DRG with behavioral pain testing","pmids":["31592410","31582966"],"confidence":"High","gaps":["Whether MZF1-AS1/PARP1 mechanism operates outside neuroblastoma not tested","Direct MZF1 binding to TRPV1 promoter not confirmed by ChIP"]},{"year":2021,"claim":"MZF1 was placed in the oncogene-induced senescence pathway: oncogenic Ras activates MZF1 via c-Jun/Ets1, and MZF1 recruits CHD7 chromatin remodeler to drive p16INK4A transcription, explaining how MZF1 can act as a tumor suppressor in primary cells.","evidence":"ChIP for MZF1 and CHD7 at CDKN2A promoter, signaling pathway inhibitors, multiple primary human cell types","pmids":["34773072"],"confidence":"High","gaps":["Whether MZF1-CHD7 interaction is direct or indirect not established","How cells escape MZF1-driven senescence during malignant transformation not addressed"]},{"year":2023,"claim":"Discovery that MZF1 promotes PD-L1 ubiquitination via CDK4 interaction linked MZF1 to immune evasion, suggesting MZF1 modulates the tumor immune microenvironment in hepatocellular carcinoma.","evidence":"Co-IP (MZF1-CDK4), ubiquitination assay, orthotopic and hydrodynamic HCC mouse models with CDK4 inhibitor","pmids":["38074509"],"confidence":"Medium","gaps":["Mechanism by which MZF1 promotes PD-L1 ubiquitination is indirect and incompletely defined","Not independently replicated","Whether this applies to other tumor types unknown"]},{"year":2025,"claim":"Identification of SUMO1-modified MZF1 nuclear bodies associated with PML-NBs expanded MZF1's biology into subnuclear compartmentalization and stress response.","evidence":"Live-cell imaging, immunofluorescence, SUMOylation assay, and proteomic interactome in PC-3 cells","pmids":["39954358"],"confidence":"Medium","gaps":["Functional consequence of MZF1-NB formation for transcription not tested","SUMOylation sites not mapped","Whether MZF1-NBs form in non-cancer cells unknown"]},{"year":null,"claim":"Key unresolved questions include: (1) the structural basis of zinc-finger domain–DNA recognition, (2) the molecular determinants that switch MZF1 between activator and repressor modes in different cell types, and (3) whether MZF1's tumor-suppressive (senescence/p16) and oncogenic (EMT/MYC) programs are cell-type exclusive or coexist with context-dependent dominance.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal/cryo-EM structure of zinc-finger–DNA complex","No genome-wide binding map (ChIP-seq) in primary hematopoietic cells","Cofactor code determining activator vs. repressor behavior not systematically defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,4,11,12,17,23,25,30,37]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,4,5,11,13,20,22,26,32,40]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[33,38,47]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,4,12,17,20,22,26,32,40]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,2,4,10]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,7,10,22,25,27]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[7,8,14,40]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,29,35,44]}],"complexes":["NF-Y/MZF1/GATA-2 enhancer complex","MZF1/Elk-1 heterodimer","MZF1 SCAN homodimer"],"partners":["ELK1","CSNK2A1","CHD7","SETD8","STUB1","CDK4","NFYA","GATA2"],"other_free_text":[]},"mechanistic_narrative":"MZF1 is a myeloid-lineage-enriched C2H2 zinc-finger transcription factor that functions as a context-dependent transcriptional activator or repressor, governing hematopoietic differentiation, oncogene-induced senescence, epithelial-mesenchymal transition, iron homeostasis, and metabolic reprogramming. It contains two independent DNA-binding domains (zinc fingers 1–4 and 5–13) recognizing distinct G-rich consensus sequences, and a SCAN domain that forms domain-swapped homodimers and mediates heterodimerization with partners such as RAZ1 and Elk-1; CK2 phosphorylation at S27 stabilizes the protein, FTO-dependent m6A demethylation stabilizes its mRNA, and SUMO1 modification enables formation of PML-NB-associated nuclear bodies [PMID:8114711, PMID:16950398, PMID:29540671, PMID:29842885, PMID:39954358]. Mzf1 knockout mice develop lethal myeloid neoplasias, establishing MZF1 as a hematopoietic tumor suppressor, yet ectopic overexpression transforms fibroblasts and promotes tumorigenesis, reflecting its dual oncogenic and tumor-suppressive roles depending on cellular context [PMID:11445537, PMID:7627970]. MZF1 directly regulates a broad target gene repertoire—including CD34, c-myb, CDKN2A/p16INK4A, N-cadherin, PKCα, ferroportin, c-MYC, IGF-IR, and TRPV1—through which it controls processes ranging from granulopoiesis and senescence to EMT, proline and glycolytic metabolism, and neuropathic pain [PMID:7579328, PMID:34773072, PMID:25884514, PMID:31582966, PMID:32042322]."},"prefetch_data":{"uniprot":{"accession":"P28698","full_name":"Myeloid zinc finger 1","aliases":["Zinc finger and SCAN domain-containing protein 6","Zinc finger protein 42"],"length_aa":734,"mass_kda":82.1,"function":"Binds to target promoter DNA and functions as a transcription regulator. Regulates transcription from the PADI1 and CDH2 promoter. May be one regulator of transcriptional events during hemopoietic development","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P28698/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MZF1","classification":"Not Classified","n_dependent_lines":285,"n_total_lines":1208,"dependency_fraction":0.2359271523178808},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MZF1","total_profiled":1310},"omim":[{"mim_id":"619677","title":"CLAUDIN DOMAIN-CONTAINING PROTEIN 1; CLDND1","url":"https://www.omim.org/entry/619677"},{"mim_id":"617889","title":"PYRIDINE NUCLEOTIDE-DISULPHIDE OXIDOREDUCTASE DOMAIN-CONTAINING PROTEIN 2; PYROXD2","url":"https://www.omim.org/entry/617889"},{"mim_id":"615321","title":"CHLORIDE INTRACELLULAR CHANNEL 6; CLIC6","url":"https://www.omim.org/entry/615321"},{"mim_id":"614336","title":"PRESEQUENCE TRANSLOCASE-ASSOCIATED MOTOR 16; PAM16","url":"https://www.omim.org/entry/614336"},{"mim_id":"613635","title":"EUKARYOTIC TRANSLATION INITIATION FACTOR 2-ALPHA KINASE 1; EIF2AK1","url":"https://www.omim.org/entry/613635"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/MZF1"},"hgnc":{"alias_symbol":["ZSCAN6","MZF1B","MZF-1","Zfp98"],"prev_symbol":["ZNF42"]},"alphafold":{"accession":"P28698","domains":[{"cath_id":"1.10.4020.10","chopping":"39-115","consensus_level":"medium","plddt":83.9545,"start":39,"end":115},{"cath_id":"3.30.160.60","chopping":"585-731","consensus_level":"medium","plddt":88.1118,"start":585,"end":731}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P28698","model_url":"https://alphafold.ebi.ac.uk/files/AF-P28698-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P28698-F1-predicted_aligned_error_v6.png","plddt_mean":65.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MZF1","jax_strain_url":"https://www.jax.org/strain/search?query=MZF1"},"sequence":{"accession":"P28698","fasta_url":"https://rest.uniprot.org/uniprotkb/P28698.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P28698/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P28698"}},"corpus_meta":[{"pmid":"29842885","id":"PMC_29842885","title":"m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29842885","citation_count":199,"is_preprint":false},{"pmid":"25531323","id":"PMC_25531323","title":"Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25531323","citation_count":188,"is_preprint":false},{"pmid":"8114711","id":"PMC_8114711","title":"Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114711","citation_count":174,"is_preprint":false},{"pmid":"1860835","id":"PMC_1860835","title":"A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1860835","citation_count":167,"is_preprint":false},{"pmid":"11445537","id":"PMC_11445537","title":"Mzf1 controls cell proliferation and tumorigenesis.","date":"2001","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11445537","citation_count":112,"is_preprint":false},{"pmid":"7565760","id":"PMC_7565760","title":"Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7565760","citation_count":105,"is_preprint":false},{"pmid":"33158815","id":"PMC_33158815","title":"Hypoxic Glioma Stem Cell-Derived Exosomes Containing Linc01060 Promote Progression of Glioma by Regulating the MZF1/c-Myc/HIF1α Axis.","date":"2020","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33158815","citation_count":105,"is_preprint":false},{"pmid":"7579328","id":"PMC_7579328","title":"The myeloid zinc finger gene, MZF-1, regulates the CD34 promoter in vitro.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7579328","citation_count":96,"is_preprint":false},{"pmid":"8585946","id":"PMC_8585946","title":"Hematopoietic transcriptional regulation by the myeloid zinc finger gene, MZF-1.","date":"1996","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8585946","citation_count":84,"is_preprint":false},{"pmid":"1719120","id":"PMC_1719120","title":"Antisense oligonucleotides from the stage-specific myeloid zinc finger gene MZF-1 inhibit granulopoiesis in vitro.","date":"1991","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1719120","citation_count":79,"is_preprint":false},{"pmid":"24793789","id":"PMC_24793789","title":"The MZF1/c-MYC axis mediates lung adenocarcinoma progression caused by wild-type lkb1 loss.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24793789","citation_count":62,"is_preprint":false},{"pmid":"7627970","id":"PMC_7627970","title":"Aberrant expression of the myeloid zinc finger gene, MZF-1, is oncogenic.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7627970","citation_count":60,"is_preprint":false},{"pmid":"15541732","id":"PMC_15541732","title":"Sp1/Sp3 and the myeloid zinc finger gene MZF1 regulate the human N-cadherin promoter in osteoblasts.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15541732","citation_count":57,"is_preprint":false},{"pmid":"25284586","id":"PMC_25284586","title":"Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.","date":"2014","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25284586","citation_count":54,"is_preprint":false},{"pmid":"16105833","id":"PMC_16105833","title":"The long terminal repeat (LTR) of ERV-9 human endogenous retrovirus binds to NF-Y in the assembly of an active LTR enhancer complex NF-Y/MZF1/GATA-2.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16105833","citation_count":50,"is_preprint":false},{"pmid":"16297876","id":"PMC_16297876","title":"PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16297876","citation_count":48,"is_preprint":false},{"pmid":"10777584","id":"PMC_10777584","title":"Identification of a novel SCAN box-related protein that interacts with MZF1B. The leucine-rich SCAN box mediates hetero- and homoprotein associations.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10777584","citation_count":46,"is_preprint":false},{"pmid":"28703907","id":"PMC_28703907","title":"TGF-β1-induced CK17 enhances cancer stem cell-like properties rather than EMT in promoting cervical cancer metastasis via the ERK1/2-MZF1 signaling pathway.","date":"2017","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/28703907","citation_count":46,"is_preprint":false},{"pmid":"9593266","id":"PMC_9593266","title":"The myeloid zinc finger gene (MZF-1) delays retinoic acid-induced apoptosis and differentiation in myeloid leukemia cells.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9593266","citation_count":46,"is_preprint":false},{"pmid":"25425970","id":"PMC_25425970","title":"Up-regulation of FOXM1 by E6 oncoprotein through the MZF1/NKX2-1 axis is required for human papillomavirus-associated tumorigenesis.","date":"2014","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/25425970","citation_count":44,"is_preprint":false},{"pmid":"29510992","id":"PMC_29510992","title":"Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.","date":"2018","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/29510992","citation_count":40,"is_preprint":false},{"pmid":"32042322","id":"PMC_32042322","title":"Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.","date":"2020","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/32042322","citation_count":39,"is_preprint":false},{"pmid":"31592410","id":"PMC_31592410","title":"Therapeutic Targeting of MZF1-AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression.","date":"2019","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/31592410","citation_count":38,"is_preprint":false},{"pmid":"15670815","id":"PMC_15670815","title":"LDOC1, a novel MZF-1-interacting protein, induces apoptosis.","date":"2005","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15670815","citation_count":38,"is_preprint":false},{"pmid":"23509792","id":"PMC_23509792","title":"p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation.","date":"2012","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/23509792","citation_count":38,"is_preprint":false},{"pmid":"31963147","id":"PMC_31963147","title":"Zinc Finger Transcription Factor MZF1-A Specific Regulator of Cancer Invasion.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31963147","citation_count":37,"is_preprint":false},{"pmid":"33533172","id":"PMC_33533172","title":"Kinase GSK3β functions as a suppressor in colorectal carcinoma through the FTO-mediated MZF1/c-Myc axis.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33533172","citation_count":35,"is_preprint":false},{"pmid":"28634046","id":"PMC_28634046","title":"Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/28634046","citation_count":34,"is_preprint":false},{"pmid":"16426580","id":"PMC_16426580","title":"MZF1 possesses a repressively regulatory function in ERCC1 expression.","date":"2006","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16426580","citation_count":33,"is_preprint":false},{"pmid":"19196427","id":"PMC_19196427","title":"Crucial roles of MZF-1 in the transcriptional regulation of apomorphine-induced modulation of FGF-2 expression in astrocytic cultures.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19196427","citation_count":29,"is_preprint":false},{"pmid":"17851584","id":"PMC_17851584","title":"Crucial roles of MZF1 and Sp1 in the transcriptional regulation of the peptidylarginine deiminase type I gene (PADI1) in human keratinocytes.","date":"2007","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/17851584","citation_count":29,"is_preprint":false},{"pmid":"28018905","id":"PMC_28018905","title":"The Mutational Landscape of the Oncogenic MZF1 SCAN Domain in Cancer.","date":"2016","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28018905","citation_count":28,"is_preprint":false},{"pmid":"17593797","id":"PMC_17593797","title":"Suppression of tumorigenicity of human hepatocellular carcinoma cells by antisense oligonucleotide MZF-1.","date":"2007","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17593797","citation_count":25,"is_preprint":false},{"pmid":"34768749","id":"PMC_34768749","title":"Irradiation Activates MZF1 to Inhibit miR-541-5p Expression and Promote Epithelial-Mesenchymal Transition (EMT) in Radiation-Induced Pulmonary Fibrosis (RIPF) by Upregulating Slug.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34768749","citation_count":25,"is_preprint":false},{"pmid":"8845378","id":"PMC_8845378","title":"Isolation and functional characterization of the human gene encoding the myeloid zinc finger protein MZF-1.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8845378","citation_count":25,"is_preprint":false},{"pmid":"8667641","id":"PMC_8667641","title":"Forced over-expression of the myeloid zinc finger gene MZF-1 inhibits apoptosis and promotes oncogenesis in interleukin-3-dependent FDCP.1 cells.","date":"1996","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8667641","citation_count":24,"is_preprint":false},{"pmid":"26010542","id":"PMC_26010542","title":"MZF-1/Elk-1 Complex Binds to Protein Kinase Cα Promoter and Is Involved in Hepatocellular Carcinoma.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26010542","citation_count":21,"is_preprint":false},{"pmid":"25884514","id":"PMC_25884514","title":"The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.","date":"2015","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25884514","citation_count":21,"is_preprint":false},{"pmid":"37250150","id":"PMC_37250150","title":"UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer.","date":"2023","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/37250150","citation_count":20,"is_preprint":false},{"pmid":"16950398","id":"PMC_16950398","title":"Structure of the SCAN domain from the tumor suppressor protein MZF1.","date":"2006","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16950398","citation_count":20,"is_preprint":false},{"pmid":"29540671","id":"PMC_29540671","title":"Phosphorylation-dependent stabilization of MZF1 upregulates N-cadherin expression during protein kinase CK2-mediated epithelial-mesenchymal transition.","date":"2018","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29540671","citation_count":20,"is_preprint":false},{"pmid":"34773072","id":"PMC_34773072","title":"MZF1 mediates oncogene-induced senescence by promoting the transcription of p16INK4A.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34773072","citation_count":16,"is_preprint":false},{"pmid":"36992161","id":"PMC_36992161","title":"Design and In Silico Validation of a Novel MZF-1-Based Multi-Epitope Vaccine to Combat Metastatic Triple Negative Breast Cancer.","date":"2023","source":"Vaccines","url":"https://pubmed.ncbi.nlm.nih.gov/36992161","citation_count":15,"is_preprint":false},{"pmid":"31184423","id":"PMC_31184423","title":"Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31184423","citation_count":15,"is_preprint":false},{"pmid":"27922669","id":"PMC_27922669","title":"Upregulation of SMAD4 by MZF1 inhibits migration of human gastric cancer cells.","date":"2016","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27922669","citation_count":15,"is_preprint":false},{"pmid":"27542222","id":"PMC_27542222","title":"MZF-1/Elk-1 interaction domain as therapeutic target for protein kinase Cα-based triple-negative breast cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27542222","citation_count":15,"is_preprint":false},{"pmid":"35350980","id":"PMC_35350980","title":"SETD8 cooperates with MZF1 to participate in hyperglycemia-induced endothelial inflammation via elevation of WNT5A levels in diabetic nephropathy.","date":"2022","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/35350980","citation_count":14,"is_preprint":false},{"pmid":"37209940","id":"PMC_37209940","title":"Asiatic acid exhibits antimetastatic activity in human prostate cancer cells by modulating the MZF-1/Elk-1/Snail signaling axis.","date":"2023","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37209940","citation_count":12,"is_preprint":false},{"pmid":"25436607","id":"PMC_25436607","title":"Myeloid zinc finger 1 (Mzf1) differentially modulates murine cardiogenesis by interacting with an Nkx2.5 cardiac enhancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25436607","citation_count":11,"is_preprint":false},{"pmid":"31582966","id":"PMC_31582966","title":"MZF1 in the Dorsal Root Ganglia Contributes to the Development and Maintenance of Neuropathic Pain via Regulation of TRPV1.","date":"2019","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/31582966","citation_count":11,"is_preprint":false},{"pmid":"38058065","id":"PMC_38058065","title":"LncRNA SLC1A5-AS/MZF1/ASCT2 Axis Contributes to Malignant Progression of Hepatocellular Carcinoma.","date":"2023","source":"Discovery medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38058065","citation_count":10,"is_preprint":false},{"pmid":"38074509","id":"PMC_38074509","title":"MZF1 promotes tumour progression and resistance to anti-PD-L1 antibody treatment in hepatocellular carcinoma.","date":"2023","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/38074509","citation_count":10,"is_preprint":false},{"pmid":"8637224","id":"PMC_8637224","title":"The location of MZF-1 at the telomere of human chromosome 19q makes it vulnerable to degeneration in aging cells.","date":"1996","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/8637224","citation_count":10,"is_preprint":false},{"pmid":"31366500","id":"PMC_31366500","title":"Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.","date":"2019","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31366500","citation_count":10,"is_preprint":false},{"pmid":"22242952","id":"PMC_22242952","title":"Expression of protein kinase C α and the MZF-1 and Elk-1 transcription factors in human breast cancer cells.","date":"2012","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22242952","citation_count":10,"is_preprint":false},{"pmid":"36499054","id":"PMC_36499054","title":"Inhibition of MZF1/c-MYC Axis by Cantharidin Impairs Cell Proliferation in Glioblastoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499054","citation_count":9,"is_preprint":false},{"pmid":"15893750","id":"PMC_15893750","title":"MZF-1 and DbpA interact with DNase I hypersensitive sites that correlate with expression of the human MUC1 mucin gene.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15893750","citation_count":9,"is_preprint":false},{"pmid":"31548308","id":"PMC_31548308","title":"The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31548308","citation_count":8,"is_preprint":false},{"pmid":"34602532","id":"PMC_34602532","title":"MZF1 alleviates oxidative stress and apoptosis induced by rotenone in SH-SY5Y cells by promoting RBM3 transcription.","date":"2021","source":"The Journal of toxicological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34602532","citation_count":8,"is_preprint":false},{"pmid":"25065746","id":"PMC_25065746","title":"The glyceraldehyde 3-phosphate dehydrogenase gene (GAPDH) is regulated by myeloid zinc finger 1 (MZF-1) and is induced by calcitriol.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25065746","citation_count":8,"is_preprint":false},{"pmid":"25899830","id":"PMC_25899830","title":"Myeloid Zinc Finger 1 (MZF-1) Regulates Expression of the CCN2/CTGF and CCN3/NOV Genes in the Hematopoietic Compartment.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25899830","citation_count":7,"is_preprint":false},{"pmid":"22559731","id":"PMC_22559731","title":"Expression of protein kinase Cα and the MZF-1 and elk-1 transcription factors in human bladder transitional cell carcinoma cells.","date":"2012","source":"The Chinese journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22559731","citation_count":7,"is_preprint":false},{"pmid":"35740998","id":"PMC_35740998","title":"Axl Expression in Renal Mesangial Cells Is Regulated by Sp1, Ap1, MZF1, and Ep300, and the IL-6/miR-34a Pathway.","date":"2022","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/35740998","citation_count":6,"is_preprint":false},{"pmid":"35669102","id":"PMC_35669102","title":"MZF1 Transcriptionally Activated MicroRNA-328-3p Suppresses the Malignancy of Stomach Adenocarcinoma via Inhibiting CD44.","date":"2022","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/35669102","citation_count":6,"is_preprint":false},{"pmid":"38373662","id":"PMC_38373662","title":"Amelioration of nitroglycerin-induced migraine in mice via Wuzhuyu decoction: Inhibition of the MZF1/PGK1 pathway and activation of NRF2 antioxidant response.","date":"2024","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38373662","citation_count":5,"is_preprint":false},{"pmid":"32449233","id":"PMC_32449233","title":"Cigarette smoke modulates binding of the transcription factor MZF1 to the VEGF promoter and regulates VEGF expression in dependence of genetic variation SNP 405.","date":"2020","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32449233","citation_count":5,"is_preprint":false},{"pmid":"39224032","id":"PMC_39224032","title":"MitoAMPK inhibits the Warburg effect by MZF1-SIRT6 with glycosis related genes in NSCLC.","date":"2024","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39224032","citation_count":5,"is_preprint":false},{"pmid":"23241556","id":"PMC_23241556","title":"Haplotype of single nucleotide polymorphisms in exon 6 of the MZF-1 gene and Alzheimer's disease.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23241556","citation_count":4,"is_preprint":false},{"pmid":"39133152","id":"PMC_39133152","title":"Solamargine acts as an antiviral by interacting to MZF1 and targeting the core promoter of the hepatitis B virus gene.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/39133152","citation_count":2,"is_preprint":false},{"pmid":"39954358","id":"PMC_39954358","title":"Discovery of myeloid zinc finger (MZF) 1 nuclear bodies.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39954358","citation_count":1,"is_preprint":false},{"pmid":"33352376","id":"PMC_33352376","title":"RETRACTED: MZF1 regulates α-globin gene transcription via long-range interactions in erythroid differentiation.","date":"2020","source":"Blood cells, molecules & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/33352376","citation_count":0,"is_preprint":false},{"pmid":"41201047","id":"PMC_41201047","title":"MicroRNA‑199a‑3p suppresses non‑small cell lung cancer progression by targeting FTO to enhance m6A‑mediated downregulation of MZF1 and its transcriptional activation of CLDND1.","date":"2025","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/41201047","citation_count":0,"is_preprint":false},{"pmid":"31607299","id":"PMC_31607299","title":"[Effects of Transcription Factor MZF-1 on Transcriptive Regulation of Acute Monocytic Leukemia-related Gene MLAA-34].","date":"2019","source":"Zhongguo shi yan xue ye xue za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31607299","citation_count":0,"is_preprint":false},{"pmid":"31934032","id":"PMC_31934032","title":"Regulation of expression of MLAA-34 gene through transcriptional factors E2F1 and MZF-1.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934032","citation_count":0,"is_preprint":false},{"pmid":"41343127","id":"PMC_41343127","title":"MZF1-AS1/NSUN2 promotes the peritoneal metastasis of gastric cancer by enhancing the stability of RAB13 mRNA.","date":"2025","source":"Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association","url":"https://pubmed.ncbi.nlm.nih.gov/41343127","citation_count":0,"is_preprint":false},{"pmid":"40961095","id":"PMC_40961095","title":"PRAME-AS lncRNA, regulated by MZF1, modulates PRAME expression and cell stemness.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40961095","citation_count":0,"is_preprint":false},{"pmid":"41003915","id":"PMC_41003915","title":"FTO-Mediated m6A Demethylation of MZF1 Regulates DECR1 to Promote Fatty Acid Oxidation and Exacerbate Myocardial Ischemia/Reperfusion Injury : FTO-Mediated m6A Demethylation of MZF1 Enhances Fatty Acid Oxidation and Aggravates Myocardial I/R Injury.","date":"2025","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41003915","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40291,"output_tokens":11903,"usd":0.149709},"stage2":{"model":"claude-opus-4-6","input_tokens":15992,"output_tokens":3722,"usd":0.259515},"total_usd":0.409224,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"MZF1 contains two independent DNA-binding domains (zinc fingers 1–4 and 5–13) that each recognize distinct but related G-rich consensus sequences (1–4: 5'-AGTGGGGA-3'; 5–13: 5'-CGGGnGAGGGGGAA-3'), as determined by affinity selection from degenerate oligonucleotide libraries and gel-shift assays with purified recombinant protein.\",\n      \"method\": \"SELEX/affinity selection from degenerate oligonucleotide library, gel-shift (EMSA) with purified recombinant protein domains\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with purified recombinant protein, two orthogonal methods, foundational study replicated by later work\",\n      \"pmids\": [\"8114711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"MZF1 is preferentially expressed in myeloid cells (highest in HL-60 cells induced with retinoic acid) and encodes a protein with 13 C2H2 zinc fingers arranged in two domains separated by a glycine-proline-rich region, localised to chromosome 19q13.2-4.\",\n      \"method\": \"cDNA library screening, sequence analysis, Northern blot, chromosomal mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original cloning and characterization paper, multiple orthogonal methods, highly cited foundational work\",\n      \"pmids\": [\"1860835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"MZF-1 antisense (but not sense) oligonucleotides significantly inhibited G-CSF-driven granulocyte colony formation in vitro, demonstrating a required role for MZF-1 in granulopoiesis.\",\n      \"method\": \"Antisense oligonucleotide inhibition of granulocyte colony formation in vitro\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean loss-of-function with defined cellular phenotype, single lab\",\n      \"pmids\": [\"1719120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"MZF1 acts as a bifunctional transcriptional regulator of the CD34 promoter: it represses transcription in non-hematopoietic cell lines (NIH 3T3, 293) and activates transcription in hematopoietic cell lines (K562, Jurkat), with activation dependent on intact MZF1 binding sites in the CD34 promoter.\",\n      \"method\": \"GAL4 fusion cotransfection reporter assay (CAT/luciferase), EMSA with recombinant MZF1, site-directed mutagenesis of binding sites\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with recombinant protein, reporter mutagenesis, multiple cell lines tested\",\n      \"pmids\": [\"7579328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Constitutive MZF1 overexpression in embryonic stem cells inhibits hematopoietic commitment and prevents induced expression of CD34 and c-myb; MZF1 binds MZF1 consensus sites in the CD34 and c-myb promoters and represses their transcriptional activity in co-transfection assays.\",\n      \"method\": \"Retroviral/stable transfection into ES cells, EMSA with recombinant MZF1, CAT reporter assay, RT-PCR\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal methods, loss- and gain-of-function, in vitro DNA binding confirmed\",\n      \"pmids\": [\"7565760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Retroviral overexpression of MZF-1 in NIH 3T3 fibroblasts causes loss of contact inhibition, loss of substrate dependence, more rapid cell cycling, and formation of aggressive tumors in athymic mice, establishing MZF-1 as an oncogene when aberrantly expressed.\",\n      \"method\": \"Retroviral transduction, focus formation assay, nude mouse tumorigenesis assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined oncogenic phenotype in vitro and in vivo, multiple readouts\",\n      \"pmids\": [\"7627970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human MZF-1 gene is intronless, spans ~3 kb, is a single-copy gene, and its promoter contains retinoic acid response elements and GM-CSF-responsive sequences that drive transcriptional responsiveness; MZF-1 can also auto-regulate its own expression via consensus zinc finger binding sites in its promoter.\",\n      \"method\": \"Genomic cloning, PCR, primer extension, CAT reporter assay with deletion constructs, retroviral overexpression in K562 cells\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter analysis with functional reporter assays, auto-regulation demonstrated by ectopic expression\",\n      \"pmids\": [\"8845378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Retroviral overexpression of MZF-1 in IL-3-dependent FDCP.1 cells inhibits apoptosis upon IL-3 withdrawal and confers tumorigenic potential in vivo, showing MZF-1 promotes cell survival and oncogenesis in a hematopoietic context.\",\n      \"method\": \"Retroviral transduction, apoptosis assay upon cytokine withdrawal, syngeneic mouse tumor formation assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function with defined apoptosis and tumorigenesis phenotypes\",\n      \"pmids\": [\"8667641\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Overexpression of MZF-1 in HL-60 cells delays retinoic acid-induced apoptosis and differentiation, sustains proliferation (higher S-phase fraction), reduces CD18 expression after 6 days RA, and is associated with prolonged bcl-2 expression; MZF-1 had no effect on PMA-induced monocyte/macrophage differentiation.\",\n      \"method\": \"Retroviral transduction/overexpression in HL-60 cells, TUNEL, DNA fragmentation, flow cytometry, Western blot for bcl-2\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal readouts (TUNEL, DPA, flow cytometry, bcl-2 protein), mechanistic link to bcl-2\",\n      \"pmids\": [\"9593266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The SCAN box (leucine-rich domain) present only in the MZF1B isoform mediates homo- and heterodimeric protein-protein interactions: MZF1B self-associates via its SCAN box and binds the novel SCAN-related protein RAZ1 (identified by yeast two-hybrid screening of a bone marrow library), as confirmed by co-immunoprecipitation.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, in vitro association assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP plus yeast two-hybrid, domain mapping performed\",\n      \"pmids\": [\"10777584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Gene-targeted Mzf1-/- mice develop lethal myeloid neoplasias with liver infiltration by chloroma-like myeloid cells, and Mzf1-/- hematopoietic progenitors show striking increases in autonomous proliferation and long-term hematopoietic capacity, demonstrating that Mzf1 acts as a tumor/growth suppressor in the hematopoietic compartment.\",\n      \"method\": \"Gene targeting (knockout mouse), histopathology, hematopoietic colony and long-term culture assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO mouse with defined cellular and tumor phenotype, replicated across multiple assays\",\n      \"pmids\": [\"11445537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF1 binds to a GA-rich core element in the N-cadherin proximal promoter in osteoblasts (identified by EMSA/supershift); cotransfection shows MZF1 overexpression increases N-cadherin promoter activity and N-cadherin mRNA expression, while Sp1/MZF1 together further enhance this effect.\",\n      \"method\": \"EMSA with osteoblast nuclear extracts and competition/supershift assays, deletion/mutation analysis, cotransfection luciferase reporter assay, RT-PCR\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA with nuclear extracts plus functional reporter with mutagenesis, single lab\",\n      \"pmids\": [\"15541732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF1 is part of a novel LTR enhancer complex NF-Y/MZF1/GATA-2 at the ERV-9 LTR upstream of the beta-globin locus: NF-Y bound at CCAAT motifs recruits MZF1 (via protein-protein interaction) and GATA-2 to neighboring GTGGGGA and GATA sites; mutation of the CCAAT motif abolishes NF-Y binding and silences downstream gene transcription.\",\n      \"method\": \"EMSA, co-IP/protein-protein interaction assays, chromatin structure analysis, stable reporter assay in K562 cells with promoter mutation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal methods, functional mutagenesis in stable cell line, identifies protein-protein interaction hierarchy\",\n      \"pmids\": [\"16105833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF-1 transcriptionally activates PKCα expression in poorly differentiated HCC cells; antisense MZF-1 oligonucleotides reduce both MZF-1 and PKCα mRNA levels and decrease cell proliferation, migration, and invasion.\",\n      \"method\": \"Antisense oligonucleotide knockdown, RT-PCR, antisense vs. sense oligonucleotide controls, migration/invasion assays, EMSA for promoter binding\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — antisense loss-of-function with multiple functional readouts, promoter binding confirmed by EMSA\",\n      \"pmids\": [\"16297876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MZF-1 interacts with the apoptosis-inducing leucine-zipper protein LDOC1 and enhances LDOC1-mediated apoptosis, as shown by co-immunoprecipitation and functional apoptosis assays.\",\n      \"method\": \"Co-immunoprecipitation, phosphatidylserine externalization assay, mitochondrial membrane potential assay, caspase-3 activity assay\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single co-IP with functional follow-up, single lab\",\n      \"pmids\": [\"15670815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MZF1 binds to a MZF1-like site in the ERCC1 promoter (EMSA with consensus oligonucleotides) and overexpression of MZF1 represses ERCC1 promoter activity; cisplatin treatment decreases MZF1 mRNA and binding activity, coinciding with increased AP1 binding and ERCC1 upregulation.\",\n      \"method\": \"EMSA, CAT reporter cotransfection assay, quantitative PCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA plus functional reporter assay, mechanistic link to drug response, single lab\",\n      \"pmids\": [\"16426580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The MZF1 SCAN domain forms a domain-swapped homodimer with a Kd ~600 nM; residues from helix 3 compose the core dimer interface; the structure was determined by NMR spectroscopy and validated by GST pull-down self-association assays.\",\n      \"method\": \"NMR structure determination, GST pull-down, tryptophan fluorescence polarization Kd measurement\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with biochemical validation, Kd determined, structure-function analysis\",\n      \"pmids\": [\"16950398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MZF1 and Sp1/Sp3 bind to the PADI1 (peptidylarginine deiminase type I) promoter in keratinocytes in vivo (confirmed by ChIP); mutation of MZF1 or Sp1 binding sites markedly reduces PADI1 promoter activity, and siRNA knockdown of MZF1 or Sp1 diminishes PADI1 expression in both low- and high-calcium conditions.\",\n      \"method\": \"Luciferase reporter with deletion/mutation constructs, ChIP assay, siRNA knockdown, qRT-PCR\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — ChIP confirms in vivo binding, mutagenesis, siRNA knockdown with defined molecular phenotype\",\n      \"pmids\": [\"17851584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"MZF-1 transcriptionally activates the FGF-2 promoter in striatal astrocytes in response to apomorphine (D1/D2 receptor agonist): a cis-element in the -785/-745 region of the FGF-2 promoter is recognized by MZF-1, and MZF-1 overexpression increases FGF-2 protein levels while MZF-1 siRNA reduces promoter activity.\",\n      \"method\": \"Promoter deletion/reporter assay, EMSA, MZF-1 plasmid overexpression and siRNA knockdown, FGF-2 protein quantification\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mapping, EMSA, and bidirectional (OE/KD) validation, single lab\",\n      \"pmids\": [\"19196427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MZF1 transcriptionally activates the p55PIK (regulatory subunit of PI3K) gene by directly binding to the TGGGGA cis-element in the p55PIK promoter (confirmed by ChIP); MZF1 overexpression increases p55PIK promoter activity and expression, leading to increased colorectal cancer cell proliferation, while MZF1 silencing has the opposite effects.\",\n      \"method\": \"ChIP assay, luciferase reporter assay, MZF1 overexpression/siRNA knockdown, cell proliferation assay\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding, bidirectional functional validation\",\n      \"pmids\": [\"23509792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MZF-1 transcriptionally regulates ferroportin (FPN) expression; increased MZF-1 promotes FPN-driven iron egress, reducing intracellular iron and restraining prostate tumor cell growth, while inhibition of MZF-1 reduces FPN, causes iron retention and enhanced tumor growth. AP4 and c-Myb jointly activate MZF1 transcription, and miR-492 directly inhibits MZF1 via its 3'UTR.\",\n      \"method\": \"siRNA/shRNA knockdown, overexpression, iron assay, xenograft tumor model, luciferase reporter for miR-492 3'UTR binding, qRT-PCR, Western blot\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, bidirectional manipulation, in vivo confirmation, upstream regulation characterized\",\n      \"pmids\": [\"25284586\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"OPN (osteopontin) induces integrin-dependent MSC expression of TGF-β1, which mediates MSC-to-CAF transformation; this pathway requires MZF1 as a transcription factor, and MZF1/TGF-β1-dependent CAF transformation promotes tumor growth and metastasis in xenograft models.\",\n      \"method\": \"In vitro co-culture with human MSCs and breast cancer lines, in vivo xenograft in NOD-scid mice, loss-of-function with siRNA/shRNA for MZF1 and TGF-β1, tumor growth/metastasis readouts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo validation, loss-of-function with defined pathway placement\",\n      \"pmids\": [\"25531323\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"LKB1 loss leads to increased MZF1 expression, which in turn drives MYC transcription; the MZF1/MYC axis mediates soft-agar growth, migration, and invasion in lung adenocarcinoma cells, and MYC inhibitors suppress LKB1-loss-induced invasiveness.\",\n      \"method\": \"shRNA knockdown of LKB1/MZF1, luciferase reporter for MYC promoter, MYC inhibitor treatment, soft-agar and invasion assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis established by knockdown plus promoter reporter, pharmacological validation\",\n      \"pmids\": [\"24793789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MZF1 directly binds the SMAD4 promoter core region (confirmed by EMSA and luciferase reporter with mutations) and activates SMAD4 transcription; MZF1 expression reduces migration of gastric adenocarcinoma cells, establishing an MZF1-SMAD4 tumor-suppressive axis.\",\n      \"method\": \"EMSA, luciferase reporter with site-directed mutagenesis, ChIP, wound-healing/Transwell migration assay\",\n      \"journal\": \"International journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — EMSA plus reporter mutagenesis plus ChIP, functional migration assay, single lab\",\n      \"pmids\": [\"27922669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MZF1 is required for FOXM1 upregulation by HPV E6 oncoprotein through the MZF1/NKX2-1 axis; NKX2-1 induced by E6 drives MZF1-mediated transcription of FOXM1, which activates Wnt/β-catenin signaling to promote tumor aggressiveness, invasiveness, and stemness.\",\n      \"method\": \"shRNA knockdown of E6/MZF1/FOXM1, luciferase reporter, nude mouse metastasis model, FOXM1 inhibitor (thiostrepton)\",\n      \"journal\": \"Neoplasia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis by sequential knockdowns in vitro and in vivo, pathway placement, single lab\",\n      \"pmids\": [\"25425970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 and Elk-1 form a heterodimeric complex that binds the PKCα promoter; Elk-1 binds the N-terminal region of MZF1 and MZF1 binds the C-terminal region of Elk-1 (confirmed by Co-IP, Re-ChIP); DNA-binding-deficient mutants of either factor reduce PKCα expression, cell proliferation, migration, invasion, and tumorigenicity in HCC.\",\n      \"method\": \"Co-IP, ChIP, Re-ChIP, luciferase reporter with DNA-binding-deficient mutants, migration/invasion/tumorigenicity assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — direct protein-protein interaction domain mapping by Co-IP, Re-ChIP confirms complex at promoter, domain mutants used for functional analysis\",\n      \"pmids\": [\"26010542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"MZF1 suppresses IGF-IR gene promoter activity in NPM-ALK+ T-cell lymphoma (confirmed by luciferase assay and ChIP); forced MZF1 expression reduces IGF-IR mRNA/protein and downstream pIGF-IR, IRS-1, AKT, and NPM-ALK phosphorylation, and decreases lymphoma cell viability, proliferation, migration, and colony formation.\",\n      \"method\": \"Luciferase reporter assay, ChIP, forced overexpression, Western blot for downstream signaling, viability/proliferation/migration/colony assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter binding, pathway epistasis shown by signaling cascade analysis, multiple functional readouts\",\n      \"pmids\": [\"25884514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The acidic domain (residues 60–72) of MZF-1 interacts with the heparin-binding domain (residues 145–157) of Elk-1 to form a heterodimer; blocking this interaction with peptide fragments (MZF-160-72 or Elk-1145-157) decreases MZF-1/Elk-1 complex formation, reduces PKCα promoter binding, and suppresses PKCα expression, migration, tumorigenicity, and EMT in triple-negative breast cancer cells.\",\n      \"method\": \"Peptide transfection to block protein-protein interaction, luciferase reporter, ChIP for PKCα promoter binding, rescue by full-length PKCα\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — domain-level PPI mapping with peptide interference, functional rescue experiment, multiple orthogonal readouts\",\n      \"pmids\": [\"27542222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MZF1 directly binds the mutational landscape of the MZF1 SCAN domain as assessed by NMR-validated conformational ensemble; the SCAN domain mediates homo- and heterodimerization and its cancer-related substitutions perturb the protein-protein interaction network of MZF1.\",\n      \"method\": \"NMR spectroscopy, molecular dynamics simulations, proteomics/RNASeq data analysis\",\n      \"journal\": \"Frontiers in molecular biosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — structural NMR with computational analysis, but functional validation of specific cancer mutations is computational only\",\n      \"pmids\": [\"28018905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β1 induces CK17 expression in cervical cancer cells via the ERK1/2-MZF1 signaling pathway; ERK1/2 inhibitors block CK17 induction, and MZF1 directly binds the CK17 promoter as identified and validated by combined computational and experimental approaches; CK17 promotes cancer stem cell properties and lymphatic metastasis without inducing EMT.\",\n      \"method\": \"ERK1/2 inhibitor treatment, MZF1 promoter binding validation (ChIP/EMSA), shRNA knockdown, in vivo metastasis assay\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis via inhibitor, direct binding confirmed, in vivo functional readout\",\n      \"pmids\": [\"28703907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MZF1 upregulates PRAME expression via direct binding to intron DNA containing MZF1 binding sites overlapping a CpG-rich region; MZF1 binding is enhanced by DNA demethylation (5-azaC treatment), and MZF1 promotes colony-forming ability in melanoma cells.\",\n      \"method\": \"Luciferase reporter, EMSA, ChIP, 5-azaC treatment, overexpression assay, colony formation assay\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus EMSA confirms direct binding, functional link to methylation status, single lab\",\n      \"pmids\": [\"28634046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FTO (m6A demethylase) enhances MZF1 mRNA expression in lung squamous cell carcinoma by reducing m6A levels on MZF1 mRNA, thereby increasing MZF1 mRNA stability; FTO knockdown decreases MZF1 expression and inhibits cell proliferation and invasion.\",\n      \"method\": \"m6A quantification, MZF1 mRNA stability assay, FTO knockdown/overexpression (including catalytic mutant), cell proliferation/apoptosis/invasion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanism established by catalytic mutant of FTO (distinguishes enzymatic from non-enzymatic effects), mRNA stability assay, multiple functional readouts\",\n      \"pmids\": [\"29842885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CK2 directly interacts with MZF1 and phosphorylates it at serine 27, which stabilizes MZF1 protein; phosphorylation-stabilized MZF1 then drives N-cadherin transcription (confirmed by ChIP), promoting EMT, cell motility and invasiveness; MZF1 knockdown reverts cancer cells from mesenchymal to epithelial morphology.\",\n      \"method\": \"Co-IP (direct CK2-MZF1 interaction), phosphorylation site mapping (S27), protein stability assay, ChIP for N-cadherin promoter, morphological analysis, migration/invasion assay\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — post-translational modification by identified kinase (CK2), phosphorylation site identified, ChIP confirms downstream transcription, multiple functional readouts\",\n      \"pmids\": [\"29540671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CHIP/STUB1 ubiquitin ligase negatively regulates MZF1 DNA-binding activity in the nucleus; loss of nuclear CHIP unleashes MZF1-driven transcription of cathepsin B/L (CTSB/L), promoting tumor cell invasion and xenograft growth in ErbB2+ breast cancer cells.\",\n      \"method\": \"Unbiased transcription factor activity screen, ectopic CHIP expression, CTSB inhibition, xenograft growth assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — unbiased screen identifies MZF1 as CHIP target, gain-of-function with defined molecular and cellular phenotype, single lab\",\n      \"pmids\": [\"29510992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1-AS1 lncRNA binds PARP1 and facilitates PARP1 interaction with E2F1, resulting in E2F1 transactivation and upregulation of MZF1 and other oncogenic genes; MZF1 in turn promotes aldehyde dehydrogenase 18A1 and PYCR1 expression to drive proline synthesis in neuroblastoma; a peptide blocking MZF1-AS1/PARP1 interaction suppresses tumor progression.\",\n      \"method\": \"RNA pulldown, co-IP (PARP1-E2F1), ChIP, luciferase reporter, small peptide blocking, lentiviral shRNA, in vivo tumor assay, amino acid profiling\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — RNA pulldown plus Co-IP identifies ternary complex, ChIP confirms transcriptional regulation, pharmacological and genetic validation in vivo\",\n      \"pmids\": [\"31592410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Sublytic C5b-9 activates the FBXO28-TRAF6 complex, which promotes K63-ubiquitination and phosphorylation of ERK5; activated ERK5 drives MZF1 expression, which then binds the RGC-32 promoter to upregulate RGC-32, causing glomerular mesangial cell proliferation in rat Thy-1 nephritis.\",\n      \"method\": \"Co-IP (FBXO28-TRAF6-ERK5), ubiquitination assay, ChIP for MZF1 at RGC-32 promoter, luciferase reporter, gene knockdown in vivo (siRNA), histology\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — protein complex identified by Co-IP, ChIP confirms MZF1-RGC-32 promoter binding, in vivo validation by gene silencing\",\n      \"pmids\": [\"31184423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 in dorsal root ganglia promotes TRPV1 expression (but not P2X7R) and contributes to neuropathic pain; CCI increases MZF1 and TRPV1 in L4/5 DRGs; viral overexpression of MZF1 induces allodynia and hyperalgesia in naïve rats, while MZF1 siRNA ameliorates CCI-induced pain behaviors.\",\n      \"method\": \"rAAV5 viral overexpression of MZF1 in DRG, MZF1 siRNA microinjection, behavioral pain testing (PWT, PWL), Western blot for TRPV1 and P2X7R\",\n      \"journal\": \"Neural plasticity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — bidirectional in vivo manipulation with defined behavioral phenotype, target gene specificity shown\",\n      \"pmids\": [\"31582966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MZF1 transcriptionally activates the Mtor promoter in a strain-specific manner in mice: a T (vs. C) at -6 relative to Tssr 40273 creates an MZF1 consensus binding site; MZF1 binds this TGGGGA element (confirmed by EMSA, DNA pulldown, and ChIP-PCR) and overexpression of MZF1 reduces Mtor promoter activity more strongly in BALB mice than DBA mice.\",\n      \"method\": \"EMSA, DNA pulldown, ChIP-PCR, luciferase reporter with allelic variants, MZF1 overexpression and Mzf1 knockdown in fibroblasts and plasmacytoma cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple biochemical methods confirm direct binding to specific site, functional reporter with allelic variants, bidirectional genetic manipulation\",\n      \"pmids\": [\"31548308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Linc01060 (lncRNA from hypoxic glioma stem cell exosomes) directly interacts with MZF1 and enhances its protein stability and nuclear translocation, enabling MZF1-mediated c-Myc transcriptional activation; c-Myc then enhances HIF1α accumulation post-transcriptionally; HIF1α feeds back by binding the Linc01060 promoter to upregulate Linc01060 transcription.\",\n      \"method\": \"RNA-protein interaction assay (Linc01060-MZF1), subcellular fractionation (nuclear translocation), co-IP, luciferase reporter (MZF1/c-Myc promoter), ChIP (HIF1α at Linc01060 promoter)\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — RNA-protein interaction shown, subcellular localization with functional consequence, ChIP and reporter confirm pathway, feedback loop established\",\n      \"pmids\": [\"33158815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"YY1 transcription factor drives MZF1 transcription; a 21-amino acid upstream open reading frame-encoded peptide (MZF1-uPEP) binds the zinc finger domain of YY1 and represses YY1 transactivation, thereby reducing MZF1 and its downstream glycolytic targets HK2 and PGK1 in neuroblastoma.\",\n      \"method\": \"Dual-luciferase assay, ChIP, Co-IP, mass spectrometry, peptide pull-down, sucrose gradient sedimentation, seahorse metabolic flux, soft agar, in vivo nude mouse assay\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal biochemical methods, peptide pull-down identifies binding domain, in vivo validation\",\n      \"pmids\": [\"32042322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MZF1 mediates oncogene-induced senescence by recruiting CHD7 to the p16INK4A (CDKN2A) promoter to drive p16INK4A transcription; MZF1 expression is itself induced by oncogenic Ras through c-Jun and Ets1 transcription factors activated by the Ras-Raf-1-MEK-ERK signaling pathway.\",\n      \"method\": \"ChIP (MZF1 and CHD7 at p16INK4A promoter), reporter assay, knockdown of MZF1/CHD7, epistasis in primary human cells from multiple origins, signaling pathway inhibitors\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms direct promoter recruitment, epistasis via inhibitors, multiple cell types validated\",\n      \"pmids\": [\"34773072\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GSK3β mediates ubiquitination of FTO demethylase, reducing FTO expression; this increases m6A modification of MZF1 mRNA, suppressing MZF1 expression and consequently decreasing c-Myc, thereby inhibiting colorectal carcinoma cell proliferation.\",\n      \"method\": \"Ubiquitination assay, m6A methylation assay on MZF1 mRNA, MZF1-FTO interaction assay (co-IP), overexpression/knockdown, in vivo tumor model with c-Myc rescue\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical mechanism of ubiquitination-dependent m6A regulation demonstrated, in vivo rescue confirms pathway, single lab\",\n      \"pmids\": [\"33533172\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Irradiation upregulates MZF1, which transcriptionally represses miR-541-5p (and its primary precursor pri-miR-541-5p); reduced miR-541-5p de-represses Slug, promoting EMT and radiation-induced pulmonary fibrosis; ectopic miR-541-5p mitigates RIPF in vivo.\",\n      \"method\": \"Irradiation model in vitro and in vivo (mouse RIPF), MZF1 knockdown/overexpression, luciferase reporter for miR-541-5p promoter, Slug knockdown, EMT marker analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transcriptional repression of miRNA by MZF1 established with reporter assay, pathway epistasis via Slug knockdown, in vivo validation\",\n      \"pmids\": [\"34768749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SETD8 (histone methyltransferase) and MZF1 co-occupy the WNT5A promoter and cooperate to regulate WNT5A expression in human glomerular endothelial cells; high glucose increases MZF1 expression and decreases SETD8 expression; SETD8 silencing expands MZF1 enrichment on the WNT5A promoter, increasing WNT5A transcription and downstream NF-κB-mediated inflammation.\",\n      \"method\": \"Co-IP (MZF1-SETD8), ChIP (MZF1 and SETD8/H4K20me1 at WNT5A promoter), dual luciferase reporter, siRNA knockdown, immunofluorescence, in vivo DN rat model\",\n      \"journal\": \"Cellular & molecular biology letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP identifies MZF1-SETD8 interaction, ChIP confirms both factors at same promoter, in vivo rat model with rescue experiment\",\n      \"pmids\": [\"35350980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MZF1 promotes PD-L1 ubiquitination and degradation by binding to the CDK4 activation site; CDK4 directly binds MZF1 and increases MZF1 expression; in turn, elevated MZF1 suppresses T-cell recruitment and confers resistance to anti-PD-L1 immunotherapy in hepatocellular carcinoma.\",\n      \"method\": \"Protein degradation assay, ubiquitination assay, co-IP (MZF1-CDK4), orthotopic and hydrodynamic mouse HCC models, CDK4 inhibitor treatment\",\n      \"journal\": \"JHEP reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and ubiquitination assays identify mechanism, in vivo pharmacological rescue, single lab\",\n      \"pmids\": [\"38074509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"UHRF1/DNMT1 complex hypermethylates an intragenic CpG island (iCpGI) in the PRSS3 gene, interfering with MZF1 binding and suppressing PRSS3-V3 expression; site-specific iCpGI demethylation (by diallyl trisulfide + 5-aza-dC) allows MZF1 to access the PRSS3 promoter and upregulate tumor-suppressive PRSS3-V3 in lung cancer cells.\",\n      \"method\": \"ChIP, luciferase reporter, bisulfite sequencing, co-IP (UHRF1-DNMT1), drug treatment, isoform-specific expression analysis\",\n      \"journal\": \"Acta pharmaceutica Sinica B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP confirms methylation-dependent MZF1 binding, epigenetic mechanism validated by drug treatment, single lab\",\n      \"pmids\": [\"37250150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SLC1A5-AS lncRNA directly binds MZF1 protein (confirmed by biotin-labeled probe pulldown and western blot), sequestering MZF1 away from the SLC1A5 promoter and relieving MZF1-mediated repression, leading to increased ASCT2 expression and enhanced glutamine uptake in hepatocellular carcinoma.\",\n      \"method\": \"Biotin-labeled RNA probe pulldown (SLC1A5-AS/MZF1 interaction), luciferase reporter, ChIP, Western blot, glutamine uptake assay, in vivo xenograft\",\n      \"journal\": \"Discovery medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RNA-protein interaction by probe pulldown, ChIP and luciferase confirm MZF1-promoter binding, single lab\",\n      \"pmids\": [\"38058065\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MZF1 forms intranuclear nuclear bodies (MZF1-NBs) that associate with PML-NBs; MZF1 is SUMO1-SUMOylated in PC-3 cells, enabling interaction with SUMO-interaction motif (SIM)-containing proteins; interactome analysis identifies MZF1-NB participation in stress response (TPR, UBAP2L), protein folding (CALR, ANKRD40), post-translational modification (TRIM33, CAMK2D, CAMK2G), and RNA binding (ALURBP, CPSF5).\",\n      \"method\": \"Live-cell imaging/immunofluorescence (nuclear body identification), proteomic/interactome analysis, SUMOylation assay, protein-protein interaction analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct subcellular localization experiment with functional consequence (nuclear body formation), SUMOylation identified, interactome by MS\",\n      \"pmids\": [\"39954358\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MZF1 is a bifunctional C2H2 zinc-finger transcription factor with two independent DNA-binding domains (ZF1–4 and ZF5–13) that recognize G-rich consensus sequences; it also contains a SCAN domain that forms domain-swapped homodimers and mediates heterodimerization with partners such as RAZ1 and Elk-1; it is stabilized by CK2-mediated phosphorylation at S27 and regulated by FTO-dependent m6A methylation of its mRNA; nuclear MZF1 forms sumoylated nuclear bodies associated with PML-NBs; acting as a context-dependent transcriptional activator or repressor of targets including CD34, c-myb, CDKN2A/p16INK4A, ferroportin, N-cadherin, IGF1R, c-MYC, VEGF, TRPV1, and multiple other genes, MZF1 controls hematopoietic differentiation, oncogene-induced senescence, iron homeostasis, EMT, glycolytic and proline metabolic reprogramming, and neuropathic pain, with its oncogenic or tumor-suppressive output determined by cellular context, interacting cofactors (NF-Y, GATA-2, SETD8, CHD7, CHIP/STUB1, CDK4), and upstream lncRNA regulators such as Linc01060 and MZF1-AS1.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MZF1 is a myeloid-lineage-enriched C2H2 zinc-finger transcription factor that functions as a context-dependent transcriptional activator or repressor, governing hematopoietic differentiation, oncogene-induced senescence, epithelial-mesenchymal transition, iron homeostasis, and metabolic reprogramming. It contains two independent DNA-binding domains (zinc fingers 1–4 and 5–13) recognizing distinct G-rich consensus sequences, and a SCAN domain that forms domain-swapped homodimers and mediates heterodimerization with partners such as RAZ1 and Elk-1; CK2 phosphorylation at S27 stabilizes the protein, FTO-dependent m6A demethylation stabilizes its mRNA, and SUMO1 modification enables formation of PML-NB-associated nuclear bodies [PMID:8114711, PMID:16950398, PMID:29540671, PMID:29842885, PMID:39954358]. Mzf1 knockout mice develop lethal myeloid neoplasias, establishing MZF1 as a hematopoietic tumor suppressor, yet ectopic overexpression transforms fibroblasts and promotes tumorigenesis, reflecting its dual oncogenic and tumor-suppressive roles depending on cellular context [PMID:11445537, PMID:7627970]. MZF1 directly regulates a broad target gene repertoire—including CD34, c-myb, CDKN2A/p16INK4A, N-cadherin, PKCα, ferroportin, c-MYC, IGF-IR, and TRPV1—through which it controls processes ranging from granulopoiesis and senescence to EMT, proline and glycolytic metabolism, and neuropathic pain [PMID:7579328, PMID:34773072, PMID:25884514, PMID:31582966, PMID:32042322].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Identification of MZF1 as a myeloid-enriched 13-zinc-finger transcription factor established the gene's tissue-specific expression pattern and structural framework, answering what kind of regulatory protein it encodes.\",\n      \"evidence\": \"cDNA library screening, Northern blot, and chromosomal mapping in myeloid cell lines\",\n      \"pmids\": [\"1860835\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No DNA-binding specificity or target genes identified\", \"Protein function unknown beyond structural prediction\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Antisense inhibition of MZF1 blocked granulocyte colony formation, providing the first functional evidence that MZF1 is required for myeloid differentiation.\",\n      \"evidence\": \"Antisense oligonucleotide treatment of G-CSF-driven colony assays\",\n      \"pmids\": [\"1719120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antisense approach lacks modern specificity controls\", \"Target genes mediating the differentiation effect unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defining two independent DNA-binding domains with distinct G-rich consensus sequences resolved how MZF1 recognizes DNA and explained its capacity to regulate diverse promoters.\",\n      \"evidence\": \"SELEX from degenerate oligonucleotide libraries and EMSA with purified recombinant domains\",\n      \"pmids\": [\"8114711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo target gene validation\", \"Structural basis of DNA recognition not yet determined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrating that MZF1 acts as an activator in hematopoietic cells but a repressor in non-hematopoietic cells on the same CD34 promoter established MZF1's context-dependent bifunctionality, while overexpression-induced transformation of NIH 3T3 cells revealed its oncogenic potential.\",\n      \"evidence\": \"Reporter assays across multiple cell types; retroviral overexpression with focus formation and nude mouse tumorigenesis\",\n      \"pmids\": [\"7579328\", \"7627970\", \"7565760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactors determining activator vs. repressor switch unidentified\", \"Mechanism of transformation not molecularly defined\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that the SCAN domain mediates homodimerization and heterodimerization with RAZ1 revealed MZF1's capacity for combinatorial protein-protein interactions beyond DNA binding.\",\n      \"evidence\": \"Yeast two-hybrid screen of bone marrow library followed by reciprocal co-immunoprecipitation\",\n      \"pmids\": [\"10777584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of RAZ1 interaction on transcription unknown\", \"Full repertoire of SCAN-mediated partners not mapped\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mzf1 knockout mice developing lethal myeloid neoplasias resolved the paradox of MZF1's dual nature by proving it functions as a tumor/growth suppressor in the hematopoietic compartment in vivo.\",\n      \"evidence\": \"Gene-targeted Mzf1−/− mice with histopathology and hematopoietic colony/long-term culture assays\",\n      \"pmids\": [\"11445537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating tumor suppression not identified\", \"Whether overexpression transforms hematopoietic cells in vivo not tested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identification of an NF-Y/MZF1/GATA-2 enhancer complex at the ERV-9 LTR and MZF1's activation of N-cadherin and PKCα broadened the target gene repertoire beyond hematopoiesis into bone biology and hepatocellular carcinoma.\",\n      \"evidence\": \"EMSA, co-IP, ChIP, and reporter mutagenesis in osteoblasts, K562, and HCC cells\",\n      \"pmids\": [\"16105833\", \"15541732\", \"16297876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of NF-Y/MZF1/GATA-2 complex for globin expression not shown\", \"How MZF1 selects targets in different tissues unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"NMR structure of the SCAN domain homodimer revealed a domain-swapped architecture with ~600 nM affinity, providing the first atomic-resolution view of MZF1's dimerization interface.\",\n      \"evidence\": \"NMR spectroscopy with GST pull-down and tryptophan fluorescence polarization\",\n      \"pmids\": [\"16950398\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of zinc-finger domains bound to DNA not solved\", \"How SCAN dimerization modulates transcriptional output unknown\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapping the MZF1–Elk-1 heterodimer interface (MZF1 acidic domain–Elk-1 heparin-binding domain) and showing that peptide disruption suppresses PKCα-driven EMT and tumorigenesis established a druggable protein-protein interaction axis.\",\n      \"evidence\": \"Co-IP, Re-ChIP, domain-mapping, peptide interference, and functional rescue in breast cancer and HCC cells\",\n      \"pmids\": [\"26010542\", \"27542222\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo pharmacokinetics and specificity of blocking peptides not characterized\", \"Whether Elk-1 interaction is required for all MZF1 oncogenic programs unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"CK2 phosphorylation at S27 was shown to stabilize MZF1 protein and drive N-cadherin-dependent EMT, while FTO-mediated m6A demethylation was shown to stabilize MZF1 mRNA, together revealing two layers of post-transcriptional/post-translational MZF1 regulation.\",\n      \"evidence\": \"Phosphorylation site mapping with kinase co-IP (CK2); FTO catalytic mutant with m6A quantification and mRNA stability assay\",\n      \"pmids\": [\"29540671\", \"29842885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other phosphorylation sites and kinases not systematically surveyed\", \"Whether CK2 and FTO pathways converge in the same tumor context unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The lncRNA MZF1-AS1 was found to recruit PARP1 to E2F1, driving MZF1 transcription and downstream proline synthesis, while MZF1 in dorsal root ganglia was linked to TRPV1-dependent neuropathic pain, greatly expanding MZF1's functional scope beyond cancer.\",\n      \"evidence\": \"RNA pulldown, co-IP, ChIP, metabolic flux in neuroblastoma; viral overexpression/siRNA in rat DRG with behavioral pain testing\",\n      \"pmids\": [\"31592410\", \"31582966\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MZF1-AS1/PARP1 mechanism operates outside neuroblastoma not tested\", \"Direct MZF1 binding to TRPV1 promoter not confirmed by ChIP\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MZF1 was placed in the oncogene-induced senescence pathway: oncogenic Ras activates MZF1 via c-Jun/Ets1, and MZF1 recruits CHD7 chromatin remodeler to drive p16INK4A transcription, explaining how MZF1 can act as a tumor suppressor in primary cells.\",\n      \"evidence\": \"ChIP for MZF1 and CHD7 at CDKN2A promoter, signaling pathway inhibitors, multiple primary human cell types\",\n      \"pmids\": [\"34773072\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MZF1-CHD7 interaction is direct or indirect not established\", \"How cells escape MZF1-driven senescence during malignant transformation not addressed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovery that MZF1 promotes PD-L1 ubiquitination via CDK4 interaction linked MZF1 to immune evasion, suggesting MZF1 modulates the tumor immune microenvironment in hepatocellular carcinoma.\",\n      \"evidence\": \"Co-IP (MZF1-CDK4), ubiquitination assay, orthotopic and hydrodynamic HCC mouse models with CDK4 inhibitor\",\n      \"pmids\": [\"38074509\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which MZF1 promotes PD-L1 ubiquitination is indirect and incompletely defined\", \"Not independently replicated\", \"Whether this applies to other tumor types unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of SUMO1-modified MZF1 nuclear bodies associated with PML-NBs expanded MZF1's biology into subnuclear compartmentalization and stress response.\",\n      \"evidence\": \"Live-cell imaging, immunofluorescence, SUMOylation assay, and proteomic interactome in PC-3 cells\",\n      \"pmids\": [\"39954358\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of MZF1-NB formation for transcription not tested\", \"SUMOylation sites not mapped\", \"Whether MZF1-NBs form in non-cancer cells unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: (1) the structural basis of zinc-finger domain–DNA recognition, (2) the molecular determinants that switch MZF1 between activator and repressor modes in different cell types, and (3) whether MZF1's tumor-suppressive (senescence/p16) and oncogenic (EMT/MYC) programs are cell-type exclusive or coexist with context-dependent dominance.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal/cryo-EM structure of zinc-finger–DNA complex\", \"No genome-wide binding map (ChIP-seq) in primary hematopoietic cells\", \"Cofactor code determining activator vs. repressor behavior not systematically defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 4, 11, 12, 17, 23, 25, 30, 37]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 4, 5, 11, 13, 20, 22, 26, 32, 40]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [33, 38, 47]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 4, 12, 17, 20, 22, 26, 32, 40]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 4, 10]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 7, 10, 22, 25, 27]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [7, 8, 14, 40]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 29, 35, 44]}\n    ],\n    \"complexes\": [\n      \"NF-Y/MZF1/GATA-2 enhancer complex\",\n      \"MZF1/Elk-1 heterodimer\",\n      \"MZF1 SCAN homodimer\"\n    ],\n    \"partners\": [\n      \"ELK1\",\n      \"CSNK2A1\",\n      \"CHD7\",\n      \"SETD8\",\n      \"STUB1\",\n      \"CDK4\",\n      \"NFYA\",\n      \"GATA2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}